|Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies|
A Antoniou, PDP Pharoah, S Narod, HA Risch, JE Eyfjord, JL Hopper, ...
The American Journal of Human Genetics 72 (5), 1117-1130, 2003
|Gene-expression profiles in hereditary breast cancer|
I Hedenfalk, D Duggan, Y Chen, M Radmacher, M Bittner, R Simon, ...
New England Journal of Medicine 344 (8), 539-548, 2001
|Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial|
A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ...
The Lancet 376 (9737), 235-244, 2010
|Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial|
MW Audeh, J Carmichael, RT Penson, M Friedlander, B Powell, ...
The Lancet 376 (9737), 245-251, 2010
|Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation|
B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, ...
Journal of clinical oncology 33 (3), 244-250, 2014
|A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general …|
AC Antoniou, X Wang, ZS Fredericksen, L McGuffog, R Tarrell, ...
Nature genetics 42 (10), 885, 2010
|Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer|
N Loman, O Johannsson, U Kristoffersson, H Olsson, A Borg
Journal of the National Cancer Institute 93 (16), 1215-1223, 2001
|Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial|
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The Lancet Oncology 18 (12), 1688-1700, 2017
|Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer|
TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ...
Jama 313 (13), 1347-1361, 2015
|Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk|
FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ...
PLoS genetics 9 (3), e1003212, 2013
|Molecular classification of familial non-BRCA1/BRCA2 breast cancer|
I Hedenfalk, M Ringnér, A Ben-Dor, Z Yakhini, Y Chen, G Chebil, R Ach, ...
Proceedings of the National Academy of Sciences 100 (5), 2532-2537, 2003
|Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors|
M Laakso, N Loman, Ĺ Borg, J Isola
Modern pathology 18 (10), 1321, 2005
|Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics|
G Jönsson, J Staaf, J Vallon-Christersson, M Ringnér, K Holm, C Hegardt, ...
Breast Cancer Research 12 (3), R42, 2010
|Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes|
N Loman, O Johannsson, PO Bendahl, Ĺ Borg, M Fernö, H Olsson
Cancer 83 (2), 310-319, 1998
|Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.|
S Hĺkansson, O Johannsson, U Johansson, G Sellberg, N Loman, ...
American journal of human genetics 60 (5), 1068, 1997
|Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene|
H Persson, A Kvist, N Rego, J Staaf, J Vallon-Christersson, L Luts, ...
Cancer research 71 (1), 78-86, 2011
|Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome|
J Staaf, M Ringnér, J Vallon-Christersson, G Jönsson, PO Bendahl, ...
Journal of Clinical Oncology 28 (11), 1813-1820, 2010
|Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families|
J Vallon-Christersson, C Cayanan, K Haraldsson, N Loman, ...
Human molecular genetics 10 (4), 353-360, 2001
|Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy|
SM Domchek, C Aghajanian, R Shapira-Frommer, RK Schmutzler, ...
Gynecologic oncology 140 (2), 199-203, 2016
|BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease|
K Haraldsson, N Loman, QX Zhang, O Johannsson, H Olsson, Ĺ Borg
Cancer research 58 (7), 1367-1371, 1998